The Latest Breaking News from HC Wainwright

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb).  The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

HC Wainwright has cut the price target for Dentsply Sirona Inc (NASDAQ:XRAY) from $58 to $48 (17% upside), reiterating the Neutral rating. The analysts have adjusted 2022 projections to reflect lower than expected Q1 FY22 earnings. Management noted that the results reflect weaker sales performance in the U.S., global supply chain challenges, and foreign exchange headwinds.…

Atreca Inc (NASDAQ:BCEL) announced a licensing agreement with Zymeworks Inc (NYSE:ZYME) to utilize their ZymeLink technology to develop novel antibody-drug conjugates (ADCs). The agreement includes a two-year research term for Atreca to evaluate antibodies as ADCs using ZymeLink with the option for a third year.  Atreca can acquire three commercial licenses to develop three unique…

HC Wainwright reiterates the Buy rating on Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a price target of $10. The analyst projects revenues of $170 million for Rolontis and $328 million for poziotinib in 2026. Eflapegrastim (formerly known as Rolontis; to be renamed) is a long-acting granulocyte colony-stimulating factor intended to stimulate neutrophil production for chemotherapy-induced neutropenia…